Ownership and insider activity for Shuttle Pharmaceuticals Holdings, Inc. (SHPH): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Price
| Price | $3.13 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50709 | $352390 | $117153 | $504749 | $8.4M | $2.6M | $1.9M | $334005 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $2.9M | 0 | 0 |
| Receivables | $49210 | $3825 | $211455 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $102460 | $613957 | $341187 | $509615 | $8.6M | $5.6M | $2.2M | $502911 |
| Property, Plant & Equipment | $18838 | $838 | $196380 | $135546 | $68714 | $358731 | $295373 | $119702 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $9.8M |
| Total Assets | $121298 | $621275 | $544047 | $651641 | $8.7M | $6.0M | $2.5M | $10.5M |
| Accounts Payable | $79104 | $30731 | $516966 | $828313 | $129245 | $283306 | $596600 | $1.5M |
| Short-term Debt | $314377 | $400000 | $686441 | $849501 | $685473 | $595999 | $874475 | 0 |
| Total Current Liabilities | $405646 | $593819 | $2.1M | $2.2M | $975676 | $1.0M | $1.5M | $8.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $135089 | 0 | 0 |
| Total Liabilities | $405646 | $593819 | $2.2M | $2.3M | $975676 | $1.9M | $1.8M | $8.2M |
| Retained Earnings | -$1.3M | -$1.9M | -$4.5M | -$5.8M | -$8.9M | -$25.4M | -$34.6M | -$46.3M |
| Total Equity | -$284348 | $27456 | -$1.7M | -$1.6M | $7.7M | $4.1M | $709152 | $2.3M |
| Total Debt | $314377 | $400000 | $874285 | $978877 | $748296 | $1.1M | $1.2M | $232147 |
| Net Debt | $263668 | $47610 | $757132 | $474128 | -$7.7M | -$4.4M | -$746672 | -$101858 |
| Working Capital | -$303186 | $20138 | -$1.8M | -$1.7M | $7.6M | $4.6M | $677148 | -$7.5M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 0.30 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -10.78 |
Profitability
| Return on Equity | -408.33% |
| Return on Invested Capital | -312.04% |
| Return on Assets | -91.63% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AKAN · BBLG · BIVI · HSCS · IMCC · ISPC · MSPR
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of SHPH: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks